1
|
Rodrigues EG, Dobroff AS, Arruda DC, Tada DB, Paschoalin T, Polonelli L. A limitless Brazilian scientist: Professor Travassos and his contribution to cancer biology. Braz J Microbiol 2023; 54:2551-2560. [PMID: 37589929 PMCID: PMC10689629 DOI: 10.1007/s42770-023-01085-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2023] [Accepted: 07/24/2023] [Indexed: 08/18/2023] Open
Abstract
Luiz Rodolpho Travassos, a Brazilian scientist recognized in several areas of research, began his studies in the field of oncology in the late 1970s when he took a sabbatical at the Memorial Sloan Kettering Cancer Center, NY, USA. At that time, the discovery and characterization of human melanoma glycoprotein antigens yielded important publications. This experience allowed 16 years later, and Dr. Travassos founded UNONEX, significantly contributing with discoveries in the area of oncology and training of researchers. This review will address all the contributions of team of researchers who, together with Dr. Travassos, collaborated with investigations into molecules and processes that lead to the development of melanoma.
Collapse
Affiliation(s)
- Elaine G Rodrigues
- Department of Microbiology, Immunology and Parasitology, Federal University of São Paulo (UNIFESP), São Paulo, SP, Brazil.
| | - Andrey S Dobroff
- University of New Mexico Comprehensive Cancer Center (UNMCCC), Albuquerque, USA
- Division of Molecular Medicine, Department of Internal Medicine, University of New Mexico (UNM) School of Medicine, Albuquerque, USA
| | - Denise C Arruda
- Integrated Group of Biotechnology, University of Mogi das Cruzes, UMC, Mogi das Cruzes, SP, Brazil
| | - Dayane B Tada
- Laboratory of Nanomaterials and Nanotoxicology, Institute of Science and Technology, Federal University of São Paulo (UNIFESP), São José dos Campos, SP, Brazil
| | - Thaysa Paschoalin
- Department of Biophysics, Federal University of São Paulo (Unifesp), São Paulo, SP, Brazil.
| | - Luciano Polonelli
- Department of Medicine and Surgery, University of Parma, Parma, Italy
| |
Collapse
|
2
|
Albert J, Janabi BA, Granell J, Hashemi MS, Sainz D, Khosa MK, Calvis C, Messeguer R, Baldomà L, Badia J, Font-Bardia M. Synthesis and biological properties of palladium(II) cyclometallated compounds derived from (E)-2-((4-hydroxybenzylidene)amino)phenol. J Organomet Chem 2022. [DOI: 10.1016/j.jorganchem.2022.122555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
3
|
Kuijpers T, Blom B. Homo and heterobimetallic palladium and platinum complexes bearing μ-diphosphane bridges involved in biological studies. Eur J Med Chem 2021; 223:113651. [PMID: 34214843 DOI: 10.1016/j.ejmech.2021.113651] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2021] [Revised: 06/10/2021] [Accepted: 06/13/2021] [Indexed: 02/03/2023]
Abstract
Given the increasing reports of well-defined bimetallic molecular complexes as potential anticancer agents in the last decades, along with the prevalence of platinum in anticancer therapy, we report here a detailed survey of bimetallic platinum and palladium complexes investigated as potential anticancer agents. Specifically, we will concentrate on the synthesis, characterisation and biological (anticancer) studies of a sub-class of these agents, namely homo and heterobimetallic complexes bearing a bridging phosphane ligand of the type: [LnM1(μ-R2P(CH2)nPR2)M2Lm] (where M1 is platinum or palladium, M2 is any other transition metal, R = alkyl or aryl substituents, Ln or Lm are co-ligands, n = 1-6). We will review the in vitro and in vivo activities and any mechanistic anticancer studies of these complexes with a view of trying to delineate patterns in biological activity and structure-activity relationships (SAR). We do not include the review of bimetallic complexes in this class that have not undergone any anticancer testing, nor those that have been involved in other biological investigations unrelated to cancer studies.
Collapse
Affiliation(s)
- Talita Kuijpers
- Maastricht Science Programme, Faculty of Science and Engineering, Maastricht University, Paul-Henri Spaaklaan, 1, PO Box 616, 6200 MD, Maastricht, the Netherlands
| | - Burgert Blom
- Maastricht Science Programme, Faculty of Science and Engineering, Maastricht University, Paul-Henri Spaaklaan, 1, PO Box 616, 6200 MD, Maastricht, the Netherlands.
| |
Collapse
|
4
|
Endo and exo cyclopalladated ( E )- N -([1,1'-biphenyl]-2-yl)-1-mesitylmethanimines: Anticancer, antibacterial and antioxidant activities. J Organomet Chem 2017. [DOI: 10.1016/j.jorganchem.2017.04.002] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
|
5
|
RIG-like Helicase Regulation of Chitinase 3-like 1 Axis and Pulmonary Metastasis. Sci Rep 2016; 6:26299. [PMID: 27198666 PMCID: PMC4873814 DOI: 10.1038/srep26299] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2015] [Accepted: 04/29/2016] [Indexed: 12/16/2022] Open
Abstract
Chi3l1 is induced by a variety of cancers where it portends a poor prognosis and plays a key role in the generation of metastasis. However, the mechanisms that Chi3l1 uses to mediate these responses and the pathways that control Chi3l1-induced tumor responses are poorly understood. We characterized the mechanisms that Chi3l1 uses to foster tumor progression and the ability of the RIG-like helicase (RLH) innate immune response to control Chi3l1 elaboration and pulmonary metastasis. Here we demonstrate that RLH activation inhibits tumor induction of Chi3l1 and the expression of receptor IL-13Rα2 and pulmonary metastasis while restoring NK cell accumulation and activation, augmenting the expression of IFN-α/β, chemerin and its receptor ChemR23, p-cofilin, LIMK2 and PTEN and inhibiting BRAF and NLRX1 in a MAVS-dependent manner. These studies demonstrate that Chi3l1 is a multifaceted immune stimulator of tumor progression and metastasis whose elaboration and tissue effects are abrogated by RLH innate immune responses.
Collapse
|
6
|
Gigli R, Pereira GJ, Antunes F, Bechara A, Garcia DM, Spindola DG, Jasiulionis MG, Caires AC, Smaili SS, Bincoletto C. The biphosphinic paladacycle complex induces melanoma cell death through lysosomal–mitochondrial axis modulation and impaired autophagy. Eur J Med Chem 2016; 107:245-54. [DOI: 10.1016/j.ejmech.2015.11.008] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2015] [Revised: 10/13/2015] [Accepted: 11/05/2015] [Indexed: 11/28/2022]
|
7
|
Ning D, Cao Y, Zhang Y, Xia L, Zhao G. Structures and antitumor activities of planar chiral cyclopalladated ferrocene derivatives. INORG CHEM COMMUN 2015. [DOI: 10.1016/j.inoche.2015.05.014] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
8
|
Ma B, Herzog EL, Lee CG, Peng X, Lee CM, Chen X, Rockwell S, Koo JS, Kluger H, Herbst RS, Sznol M, Elias JA. Role of chitinase 3-like-1 and semaphorin 7a in pulmonary melanoma metastasis. Cancer Res 2014; 75:487-96. [PMID: 25511377 DOI: 10.1158/0008-5472.can-13-3339] [Citation(s) in RCA: 55] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The prototypic chitinase-like protein Chi3l1 is induced in cancers and portends a poor prognosis, but whether it contributes to cancer progression is unknown. To address this gap in knowledge, we investigated the production of Chi3l1 in melanoma lung metastases. We found that Chi3l1 was induced during pulmonary melanoma metastasis and that this induction was regulated by the semaphorin Sema7a, interacting in stimulatory or inhibitory ways with its β1 integrin or Plexin C1 receptors, respectively. In mouse strains with genetic deletions of Chi3l1 or Sema7a, there was a significant reduction in pulmonary metastasis. Notably, antiserum raised against Chi3l1 or Sema7a phenocopied the reduction produced by genetic deletions. Melanoma lung metastasis was also decreased in the absence of IL13Rα2, a recently identified receptor for Chi3l1, consistent with a key role for Chi3l1 in melanoma spread. We confirmed roles for Sema7a and Chi3l1 in pulmonary metastasis of EMT6 breast cancer cells. Taken together, our studies establish a novel pathway through which Sem7a and its receptors regulate Chi3l1, revealing a host axis involving IL13Rα2 that plays a critical role in generating a pulmonary microenvironment that is critical to license metastasis.
Collapse
Affiliation(s)
- Bing Ma
- Department of Molecular Microbiology and Immunology, Brown University, Providence, Rhode Island
| | - Erica L Herzog
- Section of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut
| | - Chun Geun Lee
- Department of Molecular Microbiology and Immunology, Brown University, Providence, Rhode Island
| | - Xueyan Peng
- Section of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut
| | - Chang-Min Lee
- Department of Molecular Microbiology and Immunology, Brown University, Providence, Rhode Island
| | - Xiaosong Chen
- Section of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut
| | - Sara Rockwell
- Department of Therapeutic Radiology, Yale Cancer Center, New Haven, Connecticut
| | - Ja Seok Koo
- Section of Medical Oncology, Department of Internal Medicine, Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut
| | - Harriet Kluger
- Section of Medical Oncology, Department of Internal Medicine, Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut
| | - Roy S Herbst
- Section of Medical Oncology, Department of Internal Medicine, Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut
| | - Mario Sznol
- Section of Medical Oncology, Department of Internal Medicine, Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut
| | - Jack A Elias
- Department of Molecular Microbiology and Immunology, Brown University, Providence, Rhode Island. Section of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut.
| |
Collapse
|
9
|
Albert J, Granell J, Qadir R, Quirante J, Calvis C, Messeguer R, Badía J, Baldomà L, Font-Bardia M, Calvet T. Cyclopalladated Benzophenone Imines: Synthesis, Antitumor Activity, Cell Accumulation, DNA Interaction, and Cathepsin B Inhibition. Organometallics 2014. [DOI: 10.1021/om501060f] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Affiliation(s)
- Joan Albert
- Departament
de Química Inorgànica, Facultat de Química, Universitat de Barcelona, Martí i Franquès 1-11, 08028 Barcelona, Spain
- Institut
de Biomedicina, Universitat de Barcelona, 08028 Barcelona, Spain
| | - Jaume Granell
- Departament
de Química Inorgànica, Facultat de Química, Universitat de Barcelona, Martí i Franquès 1-11, 08028 Barcelona, Spain
- Institut
de Biomedicina, Universitat de Barcelona, 08028 Barcelona, Spain
| | - Romana Qadir
- Departament
de Química Inorgànica, Facultat de Química, Universitat de Barcelona, Martí i Franquès 1-11, 08028 Barcelona, Spain
| | - Josefina Quirante
- Laboratori
de Química Orgànica, Facultat de Farmàcia, Universitat de Barcelona, Av. Joan XXIII s/n, 08028 Barcelona, Spain
- Institut
de Biomedicina, Universitat de Barcelona, 08028 Barcelona, Spain
| | - Carme Calvis
- Biomed Division, LEITAT Technological Center, Parc Científic,
Edifici Hèlix, Baldiri Reixach 15-21, 08028 Barcelona, Spain
| | - Ramon Messeguer
- Biomed Division, LEITAT Technological Center, Parc Científic,
Edifici Hèlix, Baldiri Reixach 15-21, 08028 Barcelona, Spain
| | - Josefa Badía
- Departament
de Bioquímica i Biologia Molecular, Facultat de Farmàcia, Universitat de Barcelona, Av. Joan XXIII s/n, 08028 Barcelona, Spain
- Institut
de Biomedicina, Universitat de Barcelona, 08028 Barcelona, Spain
| | - Laura Baldomà
- Departament
de Bioquímica i Biologia Molecular, Facultat de Farmàcia, Universitat de Barcelona, Av. Joan XXIII s/n, 08028 Barcelona, Spain
- Institut
de Biomedicina, Universitat de Barcelona, 08028 Barcelona, Spain
| | - Mercè Font-Bardia
- Departament
de Crystallografia, Mineralogia i Dipòsits Minerals, Universitat de Barcelona, Martí i Franquès s/n, 08028 Barcelona, Spain
- Unitat
de Difracció de Raigs-X, Centre Científic
i Tecnològic de la Universitat de Barcelona, Solé i Sabarís 1-3, 08028 Barcelona, Spain
| | - Teresa Calvet
- Departament
de Crystallografia, Mineralogia i Dipòsits Minerals, Universitat de Barcelona, Martí i Franquès s/n, 08028 Barcelona, Spain
| |
Collapse
|
10
|
Bechara A, Barbosa CMV, Paredes-Gamero EJ, Garcia DM, Silva LS, Matsuo AL, Nascimento FD, Rodrigues EG, Caires ACF, Smaili SS, Bincoletto C. Palladacycle (BPC) antitumour activity against resistant and metastatic cell lines: the relationship with cytosolic calcium mobilisation and cathepsin B activity. Eur J Med Chem 2014; 79:24-33. [PMID: 24709226 DOI: 10.1016/j.ejmech.2014.03.073] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2013] [Revised: 03/24/2014] [Accepted: 03/27/2014] [Indexed: 10/25/2022]
Abstract
The search for new compounds that induce p53-independent apoptosis is the focus of many studies in cancer biology because these compounds could be more specific and would overcome chemotherapy resistance. In this study, we evaluated the in vitro antitumour activity of a Biphosphinic Palladacycle Complex (BPC) and extended preclinical studies to an in vivo model. Saos-2 cells, a p53-null human osteosarcoma drug-resistant cell line, were treated with BPC in the presence or absence of a cathepsin B inhibitor and a calcium chelator (CA074 and BAPTA-AM, respectively), and several parameters related to apoptosis were evaluated. Preclinical studies were performed with mice that were intravenously inoculated with murine melanoma B16F10-Nex2 cells and treated intraperitoneally (i.p.) with BPC (8 mg/kg/day) for ten consecutive days, when lung metastatic nodules were counted. In vitro data show that BPC induces cell death in Saos-2 cells mainly by apoptosis, which was accompanied by the effector caspase-3 activation. These events are most likely related to Bax translocation and increased cytosolic calcium mobilisation, mainly from intracellular compartments. Lysosomal Membrane Permeabilisation (LMP) was also observed after 12 h of BPC exposure. Interestingly, BAPTA-AM and CA074 significantly decreased BPC cytotoxicity, suggesting that both calcium and cathepsin B are required for BPC antitumour activity. In vivo studies demonstrated that BPC protects mice against murine metastatic melanoma. In conclusion, BPC complex is an effective anticancer compound against metastatic murine melanoma. This complex is cytotoxic to the drug-resistant osteosarcoma Saos-2 human tumour cells by inducing apoptosis triggered by calcium signalling and a lysosomal-dependent pathway.
Collapse
Affiliation(s)
- Alexandre Bechara
- Departamento de Farmacologia, EPM, Universidade Federal de São Paulo (UNIFESP), Rua Três de maio, 100 - 2nd Floor, Vila Clementino, São Paulo, SP, Brazil
| | - Christiano M V Barbosa
- Departamento de Biofísica, EPM, Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil
| | - Edgar J Paredes-Gamero
- Departamento de Biofísica, EPM, Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil
| | - Daniel M Garcia
- Departamento de Farmacologia, EPM, Universidade Federal de São Paulo (UNIFESP), Rua Três de maio, 100 - 2nd Floor, Vila Clementino, São Paulo, SP, Brazil
| | - Luís S Silva
- Unidade de Oncologia Experimental (UNONEX), EPM, Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil
| | - Alisson L Matsuo
- Unidade de Oncologia Experimental (UNONEX), EPM, Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil
| | | | - Elaine G Rodrigues
- Unidade de Oncologia Experimental (UNONEX), EPM, Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil
| | - Antonio C F Caires
- Centro Interdisciplinar de Investigação Bioquímica (CIIB), Universidade de Mogi das Cruzes, Mogi das Cruzes, SP, Brazil
| | - Soraya S Smaili
- Departamento de Farmacologia, EPM, Universidade Federal de São Paulo (UNIFESP), Rua Três de maio, 100 - 2nd Floor, Vila Clementino, São Paulo, SP, Brazil
| | - Claudia Bincoletto
- Departamento de Farmacologia, EPM, Universidade Federal de São Paulo (UNIFESP), Rua Três de maio, 100 - 2nd Floor, Vila Clementino, São Paulo, SP, Brazil.
| |
Collapse
|
11
|
|
12
|
Cyclopalladated benzophenone imines: Synthesis, cytotoxicity against human breast adenocarcinoma cell lines and DNA interaction. J Organomet Chem 2013. [DOI: 10.1016/j.jorganchem.2012.11.034] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
13
|
Carreira M, Calvo-Sanjuán R, Sanaú M, Marzo I, Contel M. Organometallic Palladium Complexes with a Water-Soluble Iminophosphorane Ligand as Potential Anticancer Agents. Organometallics 2012; 31:5772-5781. [PMID: 23066172 PMCID: PMC3466594 DOI: 10.1021/om3006239] [Citation(s) in RCA: 69] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
The synthesis and characterization of a new water-soluble iminophosphorane ligand TPA=N-C(O)-2BrC(6)H(4) (C,N-IM; TPA = 1,3,5-triaza-7-phosphaadamantane) 1 is reported. Oxidative addition of 1 to Pd(2)(dba)(3) affords the orthopalladated dimer [Pd(μ-Br){C(6)H(4)(C(O)N=TPA-kC,N)-2}](2) (2) as a mixture of cis and trans isomers (1:1 molar ratio) where the iminophosphorane moeity behaves as a C,N-pincer ligand. By addition of different neutral or monoanionic ligands to 2, the bridging bromide can be cleaved and a variety of hydrophilic or water-soluble mononuclear organometallic palladium(II) complexes of the type [Pd{C(6)H(4)(C(O)N=TPA-kC,N)-2}(L-L)] (L-L = acac (3); S(2)CNMe(2) (4); 4,7-Diphenyl-1,10-phenanthrolinedisulfonic acid disodium salt C(12)H(6)N(2)(C(6)H(4)SO(3)Na)(2) (5)); [Pd{C(6)H(4)(C(O)N=TPA-kC,N)-2}(L)Br] (L = P(mC(6)H(4)SO(3)Na)(3) (6); P(3-Pyridyl)(3) (7)) and, [Pd(C(6)H(4)(C(O)N=TPA)-2}(TPA)(2)Br] (8) are obtained as single isomers. All new complexes were tested as potential anticancer agents and their cytotoxicity properties were evaluated in vitro against human Jurkat-T acute lymphoblastic leukemia cells, normal T-lymphocytes (PBMC) and DU-145 human prostate cancer cells. Compounds [Pd(μ-Br){C(6)H(4)(C(O)N=TPA-kC,N)-2}](2) (2) and [Pd{C(6)H(4)(C(O)N=TPA-kC,N)-2}(acac)] 3 (which has been crystallographically characterized) display the higher cytotoxicity against the above mentioned cancer cell lines while being less toxic to normal T-lymphocytes (peripheral blood mononuclear cells: PBMC). In addition, 3 is very toxic to cisplatin resistant Jurkat shBak indicating a cell death pathway that may be different to that of cisplatin. The interaction of 2 and 3 with plasmid (pBR322) DNA is much weaker than that of cisplatin pointing to an alternative biomolecular target for these cytotoxic compounds. All the compounds show an interaction with human serum albumin (HSA) faster than that of cisplatin.
Collapse
Affiliation(s)
- Monica Carreira
- Department of Chemistry, Brooklyn College and The Graduate Center, The City University of New York, Brooklyn, NY, 11210, US
| | - Rubén Calvo-Sanjuán
- Department of Biochemistry and Molecular and Cellular Biology, University of Zaragoza, 50009, Spain
| | - Mercedes Sanaú
- Departamento de Química Inorgánica, Universidad de Valencia, Burjassot, Valencia, 46100, Spain
| | - Isabel Marzo
- Department of Biochemistry and Molecular and Cellular Biology, University of Zaragoza, 50009, Spain
| | - María Contel
- Department of Chemistry, Brooklyn College and The Graduate Center, The City University of New York, Brooklyn, NY, 11210, US
| |
Collapse
|
14
|
A cyclopalladated complex interacts with mitochondrial membrane thiol-groups and induces the apoptotic intrinsic pathway in murine and cisplatin-resistant human tumor cells. BMC Cancer 2011; 11:296. [PMID: 21756336 PMCID: PMC3156809 DOI: 10.1186/1471-2407-11-296] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2010] [Accepted: 07/14/2011] [Indexed: 12/11/2022] Open
Abstract
Background Systemic therapy for cancer metastatic lesions is difficult and generally renders a poor clinical response. Structural analogs of cisplatin, the most widely used synthetic metal complexes, show toxic side-effects and tumor cell resistance. Recently, palladium complexes with increased stability are being investigated to circumvent these limitations, and a biphosphinic cyclopalladated complex {Pd2 [S(-)C2, N-dmpa]2 (μ-dppe)Cl2} named C7a efficiently controls the subcutaneous development of B16F10-Nex2 murine melanoma in syngeneic mice. Presently, we investigated the melanoma cell killing mechanism induced by C7a, and extended preclinical studies. Methods B16F10-Nex2 cells were treated in vitro with C7a in the presence/absence of DTT, and several parameters related to apoptosis induction were evaluated. Preclinical studies were performed, and mice were endovenously inoculated with B16F10-Nex2 cells, intraperitoneally treated with C7a, and lung metastatic nodules were counted. The cytotoxic effects and the respiratory metabolism were also determined in human tumor cell lines treated in vitro with C7a. Results Cyclopalladated complex interacts with thiol groups on the mitochondrial membrane proteins, causes dissipation of the mitochondrial membrane potential, and induces Bax translocation from the cytosol to mitochondria, colocalizing with a mitochondrial tracker. C7a also induced an increase in cytosolic calcium concentration, mainly from intracellular compartments, and a significant decrease in the ATP levels. Activation of effector caspases, chromatin condensation and DNA degradation, suggested that C7a activates the apoptotic intrinsic pathway in murine melanoma cells. In the preclinical studies, the C7a complex protected against murine metastatic melanoma and induced death in several human tumor cell lineages in vitro, including cisplatin-resistant ones. The mitochondria-dependent cell death was also induced by C7a in human tumor cells. Conclusions The cyclopalladated C7a complex is an effective chemotherapeutic anticancer compound against primary and metastatic murine and human tumors, including cisplatin-resistant cells, inducing apoptotic cell death via the intrinsic pathway.
Collapse
|
15
|
Guimaraes-Correa AB, Crawford LB, Figueiredo CR, Gimenes KP, Pinto LA, Rios Grassi MF, Feuer G, Travassos LR, Caires AC, Rodrigues EG, Marriott SJ. C7a, a biphosphinic cyclopalladated compound, efficiently controls the development of a patient-derived xenograft model of adult T cell leukemia/lymphoma. Viruses 2011; 3:1041-1058. [PMID: 21994769 PMCID: PMC3185797 DOI: 10.3390/v3071041] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2011] [Revised: 06/17/2011] [Accepted: 06/17/2011] [Indexed: 02/02/2023] Open
Abstract
Adult T-cell leukemia/lymphoma (ATLL) is a highly aggressive disease that occurs in individuals infected with the human T lymphotropic virus type 1 (HTLV-1). Patients with aggressive ATLL have a poor prognosis because the leukemic cells are resistant to conventional chemotherapy. We have investigated the therapeutic efficacy of a biphosphinic cyclopalladated complex {Pd2 [S(−)C2, N-dmpa]2 (μ-dppe)Cl2}, termed C7a, in a patient-derived xenograft model of ATLL, and investigated the mechanism of C7a action in HTLV-1-positive and negative transformed T cell lines in vitro. In vivo survival studies in immunocompromised mice inoculated with human RV-ATL cells and intraperitoneally treated with C7a led to significantly increased survival of the treated mice. We investigated the mechanism of C7a activity in vitro and found that it induced mitochondrial release of cytochrome c, caspase activation, nuclear condensation and DNA degradation. These results suggest that C7a triggers apoptotic cell death in both HTLV-1 infected and uninfected human transformed T-cell lines. Significantly, C7a was not cytotoxic to peripheral blood mononuclear cells (PBMC) from healthy donors and HTLV-1-infected individuals. C7a inhibited more than 60% of the ex vivo spontaneous proliferation of PBMC from HTLV-1-infected individuals. These results support a potential therapeutic role for C7a in both ATLL and HTLV-1-negative T-cell lymphomas.
Collapse
Affiliation(s)
- Ana B. Guimaraes-Correa
- Unidade de Oncologia Experimental, Departamento de Microbiologia, Imunologia e Parasitologia, Universidade Federal de São Paulo (UNIFESP-EPM), São Paulo 04023-062, Brazil; E-Mails: (A.B.G.-C.); (C.R.F.); (K.P.G.); (L.R.T.); (E.G.R.)
| | - Lindsey B. Crawford
- Department of Microbiology and Immunology, SUNY Upstate Medical University, Syracuse, NY 13210, USA; E-Mail: (L.B.C.)
| | - Carlos R. Figueiredo
- Unidade de Oncologia Experimental, Departamento de Microbiologia, Imunologia e Parasitologia, Universidade Federal de São Paulo (UNIFESP-EPM), São Paulo 04023-062, Brazil; E-Mails: (A.B.G.-C.); (C.R.F.); (K.P.G.); (L.R.T.); (E.G.R.)
| | - Karina P. Gimenes
- Unidade de Oncologia Experimental, Departamento de Microbiologia, Imunologia e Parasitologia, Universidade Federal de São Paulo (UNIFESP-EPM), São Paulo 04023-062, Brazil; E-Mails: (A.B.G.-C.); (C.R.F.); (K.P.G.); (L.R.T.); (E.G.R.)
| | - Lorena A. Pinto
- Laboratorio Avançado de Saúde Pública, CPQGM, Fundação Oswaldo Cruz (FIOCRUZ), Salvador, Bahia 40296-700, Brazil; E-Mails: (L.A.P.); (M.F.R.G.)
| | - Maria Fernanda Rios Grassi
- Laboratorio Avançado de Saúde Pública, CPQGM, Fundação Oswaldo Cruz (FIOCRUZ), Salvador, Bahia 40296-700, Brazil; E-Mails: (L.A.P.); (M.F.R.G.)
| | - Gerold Feuer
- Humurine Technologies, Inc., 640 Arrow Highway, La Verne, CA 91750, USA; E-Mail: (G.F.)
| | - Luiz R. Travassos
- Unidade de Oncologia Experimental, Departamento de Microbiologia, Imunologia e Parasitologia, Universidade Federal de São Paulo (UNIFESP-EPM), São Paulo 04023-062, Brazil; E-Mails: (A.B.G.-C.); (C.R.F.); (K.P.G.); (L.R.T.); (E.G.R.)
| | - Antonio C.F. Caires
- Centro Interdisciplinar de Investigação Bioquímica, Universidade de Mogi de Cruzes, Mogi das Cruzes, São Paulo 08780-911, Brazil; E-Mail: (A.C.F.C.)
| | - Elaine G. Rodrigues
- Unidade de Oncologia Experimental, Departamento de Microbiologia, Imunologia e Parasitologia, Universidade Federal de São Paulo (UNIFESP-EPM), São Paulo 04023-062, Brazil; E-Mails: (A.B.G.-C.); (C.R.F.); (K.P.G.); (L.R.T.); (E.G.R.)
| | - Susan J. Marriott
- Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, TX 77030, USA
- Author to whom correspondence should be addressed; E-Mail: ; Tel.: +1-713-798-4440; Fax: +1-713-798-4435
| |
Collapse
|
16
|
Marchi LHL, Paschoalin T, Travassos LR, Rodrigues EG. Gene therapy with interleukin-10 receptor and interleukin-12 induces a protective interferon-γ-dependent response against B16F10-Nex2 melanoma. Cancer Gene Ther 2010; 18:110-22. [DOI: 10.1038/cgt.2010.58] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
17
|
Dias BR, Rodrigues EG, Nimrichter L, Nakayasu ES, Almeida IC, Travassos LR. Identification of iGb3 and iGb4 in melanoma B16F10-Nex2 cells and the iNKT cell-mediated antitumor effect of dendritic cells primed with iGb3. Mol Cancer 2009; 8:116. [PMID: 19968878 PMCID: PMC2795753 DOI: 10.1186/1476-4598-8-116] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2009] [Accepted: 12/07/2009] [Indexed: 01/23/2023] Open
Abstract
Background CD1d-restricted iNKT cells are protective against murine melanoma B16F10-Nex2 growing subcutaneously in syngeneic C57Bl/6 mice as inferred from the fast tumor development in CD1d-KO in comparison with wild type animals. CD1d glycoproteins are related to the class I MHC molecules, and are involved in the presentation, particularly by dentritic cells (DC), of lipid antigens to iNKT cells. In the present work we attempted to identify the endogenous lipid mediator expressed in melanoma cells inducing such immunesurveillance response and study the possibility of protecting animals challenged with tumor cells with lipid-primed DC. Results Crude cytosolic and membrane fractions from in vivo growing melanoma contained iNKT-stimulating substances. Lipids were then extracted from these cells and one of the fractions (i.e. F3A) was shown to prime bone marrow-derived dendritic cells (BMDC) to stimulate iNKT murine hybridoma (DN32D3) cells to produce IL-2. The active fraction was analyzed by electrospray ionization-mass spectrometry (ESI-LIT-MS) and both iGb3 and iGb4 were identified along with GM3. When iGb3 was incubated with BMDC and tested with DN32D3 cells, IL-2 was equally produced indicating iNKT cell activation. GM3 consistently inhibited this response. To assess the antitumor response-induced by iGb3, a cytotoxicity assay in vitro was used with [3H]-thymidine labeled B16F10-Nex2 cells. At target/effector (iGb3-activated iNKT) cell ratio of 100-1-100-4 tumor cell lysis was shown. The antitumor activity in vivo was tested in mice challenged i.v. with B16F10-Nex2 cells and treated with iGb3- or α-galactosylceramide-primed DCs. A 4-fold lower tumor load in the lungs was observed with either treatment. Conclusion Our results show the expression of globo and isoglobohexosylceramides in murine melanoma B16F10-Nex2. The expression of iGb3 and its precursor, iGb4, on tumor cells may prime an effective iNKT cell-dependent antitumor response, modulated negatively by GM3 which is also produced in these cells. iGb3-primed BMDC exerted a significant iNKT cell-mediated anti-tumor activity in mice challenged with melanoma cells.
Collapse
Affiliation(s)
- Bianca R Dias
- Experimental Oncology Unit (UNONEX), Department of Microbiology, Immunology and Parasitology, Universidade Federal de São Paulo, São Paulo, Brazil.
| | | | | | | | | | | |
Collapse
|